Supplementary Figure 1 from Spectrin Repeat Containing Nuclear Envelope 1 and Forkhead Box Protein E1 Are Promising Markers for the Detection of Colorectal Cancer in Blood

Autor: Manon van Engeland, Nita Ahuja, Gerrit A. Meijer, Wim van Criekinge, Stephen B. Baylin, James G. Herman, Kornel E. Schuebel, Joost Louwagie, Kim A.D. Wouters, Hanneke E.C. Niessen, Leander Van Neste, Kim M. Smits, Marjolein H.F.M. Lentjes, Joo Mi Yi, Veerle Melotte

Supplementary Figure 1. Study population test and training set

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64a962282e14748219f11c622cb955f4
https://doi.org/10.1158/1940-6207.22524861

Supplementary Table 2 from Spectrin Repeat Containing Nuclear Envelope 1 and Forkhead Box Protein E1 Are Promising Markers for the Detection of Colorectal Cancer in Blood

Autor: Manon van Engeland, Nita Ahuja, Gerrit A. Meijer, Wim van Criekinge, Stephen B. Baylin, James G. Herman, Kornel E. Schuebel, Joost Louwagie, Kim A.D. Wouters, Hanneke E.C. Niessen, Leander Van Neste, Kim M. Smits, Marjolein H.F.M. Lentjes, Joo Mi Yi, Veerle Melotte

Supplementary Table 2. Primers and Beacons

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cf815055ae6194f58c00830aa483acb
https://doi.org/10.1158/1940-6207.22524855

Data from GATA4 and GATA5 are Potential Tumor Suppressors and Biomarkers in Colorectal Cancer

Autor: Manon van Engeland, Adriaan P. de Bruïne, James G. Herman, Stephen B. Baylin, Gerrit A. Meijer, Beatriz Carvalho, Wim van Criekinge, Joost Louwagie, Matty P. Weijenberg, Daisy Jonkers, Carolina A.J. Khalid-de Bakker, Silvia Sanduleanu, Yasuhito Yuasa, Yoshimitsu Akiyama, Kim M. Smits, Kathleen L.J. Daenen, Kim A.D. Wouters, Veerle Melotte, Sandra M. van den Bosch, Marjolein H.F.M. Lentjes, Debby M.E.I. Hellebrekers

Purpose: The transcription factors GATA4 and GATA5 are involved in gastrointestinal development and are inactivated by promoter hypermethylation in colorectal cancer. Here, we evaluated GATA4/5 promoter methylation as potential biomarkers for noninva

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a1e98cf39c3f0ec84f2d7af164dc166
https://doi.org/10.1158/1078-0432.c.6517879

Survival Is Related to Estrogen Signal Transduction Pathway Activity in Postmenopausal Women Diagnosed with High-Grade Serous Ovarian Carcinoma

Autor: Yvonne Wesseling-Rozendaal, Marjolein H.F.M. Lentjes-Beer, Jurgen M.J. Piek, Joanne A. de Hullu, Ruud L.M. Bekkers, Caroline Vos, Anja van de Stolpe, Steven L. Bosch, Laura A.M. van Lieshout, Meggy P.M. Ottenheijm, Leon F.A.G. Massuger, Phyllis van der Ploeg, Annelen Meriaan

Publikováno v: Cancers
Volume 13
Issue 20
Cancers, 13(20):5101. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, Vol 13, Iss 5101, p 5101 (2021)
Cancers, 13
Cancers, 13, 20

High-grade serous ovarian carcinoma (HGSC), the most common subtype of ovarian cancer, has a high mortality rate. Although there are some factors associated with survival, such as stage of disease, there are remarkable differences in survival among w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36624e788cfa97a02203274693515ee3

Identification of signal transduction pathway activity with potential clinical target in high-grade serous ovarian and tubal carcinoma

Autor: Yvonne Wesseling-Rozendaal, M. Caroline Vos, Ruud L.M. Bekkers, Paul J. van Diest, Laura A.M. van Lieshout, Jurgen M.J. Piek, Joanne A. de Hullu, Phyllis van der Ploeg, Steven L. Bosch, Anja van de Stolpe, Marjolein H.F.M. Lentjes-Beer

Publikováno v: Journal of Clinical Oncology. 39:e17541-e17541

e17541 Background: High-grade serous carcinoma (HGSC) is the most common subtype of epithelial ovarian and tubal cancer. It has a high mortality rate, even after successful first-line treatment with debulking surgery and chemotherapy. Although therap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3c9616387023b9fb2a1df45c44555f22
https://doi.org/10.1200/jco.2021.39.15_suppl.e17541